Definium Therapeutics, Inc. (DFTX) stock
DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$32.08−0.92 (-2.79%)
Close on Nov 13, 2026Market cap $4.31BP/E –Yield –
Earnings
Definium Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.46
-$0.78 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Definium Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | – | – | -$0.46 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | – | – | -$1.44 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | – | – | -$0.71 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026during market hours | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | – | – | -$0.78 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025during market hours | – | – | -$0.50 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | – | – | -$0.35 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 6, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024before the open | – | – | -$0.26 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | – | – | -$1.14 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | – | – | -$0.45 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | – | – | -$0.76 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023during market hours | – | – | -$0.65 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023during market hours | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$0.56 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022during market hours | – | – | -$0.04 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | -$0.04 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022during market hours | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Definium Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Definium Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Definium Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- News
- Update
- Update
- Results
- News
- News
- Update
- Update
- News
- News
- Results
- News
See a number that looks wrong?